LUNG CANCER: Studies of patient biopsies and preclinical models imply that activating EGFR mutations drive an immunosuppressive tumour microenvironment, and suggest synergy for combination EGFR/PD-1 inhibition.
Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non–small cell lung cancer.
Science Immunology, Jan 31th 2020
https://immunology.sciencemag.org/content/5/43/eaav3937/tab-pdf